Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05283902 |
Other study ID # |
FUES05 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
March 19, 2022 |
Est. completion date |
October 2022 |
Study information
Verified date |
March 2022 |
Source |
Federal University of Espirito Santo |
Contact |
Valeria Valim, PhD |
Phone |
2733157899 |
Email |
val.valim[@]gmail.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The objective of this observational case-crossover study is to evaluate the effectiveness,
safety and immunogenicity of the second booster dose in the elderly. There are an estimated
490,000 eligible individuals aged 60 and over statewide for the effectiveness study. Two
hundred and forty participants will be invited to participate in biological sample for the
immunogenicity study. This sub-sample will be compared with 240 biorepository samples from a
cohort of immunosuppressed patients with autoimmune diseases who received the fourth dose, in
a study conducted by the same team of researchers. The main effectiveness outcome will be the
number of hospitalizations; and secondary outcomes will be deaths, number of reported cases,
number of cases confirmed by RT-PCR. The safety assessment will be carried out by monitoring
adverse events. The cellular and humoral immune response will be evaluated by viral
neutralization assay (search for neutralizing antibodies), serological assay by
chemiluminescence, determination of specific IgM and IgG profile, dosage of soluble systemic
factors (chemokines, cytokines and growth factors), stimulation in vitro antigen-specific
peripheral blood mononuclear cells and investigation of memory T and B lymphocytes and
intracytoplasmic cytokines. The study hypothesis is that elderly people who received the
second booster dose have a lower incidence rate of hospitalizations and death than those who
received the primary regimen (two doses or one of Janssen) or a booster dose, and that the
immune response humoral and cellular function of the elderly is similar to those who are
immunosuppressed.
Description:
Faced with the new scenario of high transmission of the Ômicron variant of SARS-COV-2, in
which the elderly over 60 years and immunosuppressed even vaccinated with three doses have
become a population vulnerable to a greater probability of serious illness by Covid-19,
demanding an increase in risk of hospitalization and deaths, the application of the fourth
dose (second booster dose) has become an alternative to increase protection for these
individuals. The general objective of this study is to evaluate the effectiveness, safety and
immunogenicity of the second booster dose in the elderly. This is an observational,
case-crossover study, based on databases with notification and vaccination records and a
cohort study for the analysis of immunogenicity. Elderly people of both sexes aged 60 years
or older, residents of Espírito Santo, will be included. There are an estimated 490,000
eligible individuals aged 60 and over statewide for the effectiveness study. Two hundred and
forty participants, with quotas distributed by sex (50% male and 50% female) and age group,
will be invited to participate in biological sample collection on the day of application of
the second booster dose (T1) , 28 days after the second booster dose (T2), at the follow-up
visit after 3 months (T3), 150 days (T4) and 180 days (T5), for follow-up of vaccine response
and follow-up of duration of immunity, in a health unit in Cariacica-ES. This sub-sample will
be compared with 240 biorepository samples from a cohort of immunosuppressed patients with
autoimmune diseases who received the fourth dose, in a study conducted by the same team of
researchers. The main effectiveness outcome will be the number of hospitalizations, weighted
by protection time, 90 days after complete immunization (14th day after second booster dose);
and secondary outcomes will be deaths, number of reported cases, number of cases confirmed by
RT-PCR. The safety assessment will be carried out by monitoring adverse events. The cellular
and humoral immune response will be evaluated by viral neutralization assay (search for
neutralizing antibodies), serological assay by chemiluminescence, determination of specific
IgM and IgG profile, dosage of soluble systemic factors (chemokines, cytokines and growth
factors), stimulation in vitro antigen-specific peripheral blood mononuclear cells and
investigation of memory T and B lymphocytes and intracytoplasmic cytokines. The study
hypothesis is that elderly people who received the second booster dose have a lower incidence
rate of hospitalizations and death than those who received the primary regimen (two doses or
one of Janssen) or a booster dose, and that the immune response humoral and cellular function
of the elderly is similar to those who are immunosuppressed.